Shots:
- The first patient has been dosed in a P-III clinical study evaluating the efficacy and safety of BAT2206 vs reference Stelara in ~ 472 patients with moderately to severely PsO
- BAT2206 represents the 4th biosimilar of Bio-Thera’s portfolio to enter P-III study. The advancement of BAT2206 in P-III study demonstrates company’s commitment to develop biosimilars to expand patient access at lower costs
- Bio-Thera Solutions is developing additional proposed biosimilars, including a bevacizumab biosimilar and a tocilizumab biosimilar that have completed global P- III clinical trials. The company is also pursuing biosimilar versions of golimumab, mepolizumab, and dupilumab
Click here to read the full press release/ article | Ref: Businesswire | Image: Businesswire
The post Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab) first appeared on PharmaShots.
